With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
BMY trades against a final fair-value range of $68.85-$100.89, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Bristol-Myers Squibb is facing a massive loss of exclusivity wave. A failure in executing its new product launches would transform its 9.1x distressed multiple into a value trap, threatening the sustainability of its 70% dividend payout.
New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.
Regulatory and pricing pressures under the Inflation Reduction Act permanently compress operating margins well below the projected 29%.
Management pursues aggressively overpriced acquisitions to patch the pipeline gap, significantly destroying ROIC and elevating debt.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $46.16B | $45.01B-2.5% | $48.30B+7.3% | $48.20B-0.2% | +1.4% |
| Gross profit | $36.02B | $34.31B | $34.33B | $34.26B | -1.7% |
| Operating income | $9.10B | $8.20B | $5.89B | $13.72B | +14.7% |
| Net income | $6.33B | $8.03B+26.9% | $-8.95B | $7.05B | +3.7% |
| EPS (diluted) | $2.95 | $3.86 | $-4.41 | $3.46 | +5.5% |
| EBITDA | $19.22B | $19.37B | $3.17B | $15.23B | -7.5% |
| R&D | $9.51B | $9.30B | $11.16B | $9.95B | +1.5% |
| SG&A | $7.81B | $7.77B | $8.41B | $7.27B | -2.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Failure to revert the suppressed 0.32x Capex/DA ratio. | Monitor | Deterioration versus the report thesis |
| Management messaging hinting at dividend payout adjustments. | Monitor | Deterioration versus the report thesis |
